NicOx S.A.-Product Pipeline Review-2016

NicOx S.A.-Product Pipeline Review-2016

  • Products Id :- GMDHC08112CDB
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

NicOx S.A.-Product Pipeline Review-2016


Global Markets Direct's, NicOx S.A.-Product Pipeline Review-2016', provides an overview of the NicOx S.A.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NicOx S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the pipeline therapeutic landscape of NicOx S.A.

The report provides overview of NicOx S.A. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses NicOx S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features NicOx S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate NicOx S.A.'s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for NicOx S.A.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding NicOx S.A.'s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

NicOx S.A. Snapshot 6

NicOx S.A. Overview 6

Key Information 6

Key Facts 6

NicOx S.A.-Research and Development Overview 7

Key Therapeutic Areas 7

NicOx S.A.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

NicOx S.A.-Pipeline Products Glance 14

NicOx S.A.-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Filing rejected/Withdrawn Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

NicOx S.A.-Clinical Stage Pipeline Products 17

Phase I Products/Combination Treatment Modalities 17

NicOx S.A.-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

NicOx S.A.-Drug Profiles 19

cetirizine hydrochloride 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

naproxcinod 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

azithromycin 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

bromfenac sodium 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

fluticasone propionate 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

cerdulatinib 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ISV-405 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

NCX-1021 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

NCX-1653 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NCX-250 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

NCX-422 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

NCX-429 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

NCX-434 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

NCX-466 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

NCX-470 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

NCX-667 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

NicOx S.A.-Pipeline Analysis 38

NicOx S.A.-Pipeline Products by Target 38

NicOx S.A.-Pipeline Products by Route of Administration 40

NicOx S.A.-Pipeline Products by Molecule Type 41

NicOx S.A.-Pipeline Products by Mechanism of Action 42

NicOx S.A.-Recent Pipeline Updates 44

NicOx S.A.-Dormant Projects 56

NicOx S.A.-Discontinued Pipeline Products 57

Discontinued Pipeline Product Profiles 57

naproxcinod 57

NCX-1000 57

NCX-1236 57

NCX-226 57

NCX-285 58

NCX-6560 58

NicOx S.A.-Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

NicOx S.A., Key Information 6

NicOx S.A., Key Facts 6

NicOx S.A.-Pipeline by Indication, 2016 9

NicOx S.A.-Pipeline by Stage of Development, 2016 10

NicOx S.A.-Monotherapy Products in Pipeline, 2016 11

NicOx S.A.-Partnered Products in Pipeline, 2016 12

NicOx S.A.-Partnered Products/ Combination Treatment Modalities, 2016 13

NicOx S.A.-Pre-Registration, 2016 14

NicOx S.A.-Filing rejected/Withdrawn, 2016 15

NicOx S.A.-Phase III, 2016 16

NicOx S.A.-Phase I, 2016 17

NicOx S.A.-Preclinical, 2016 18

NicOx S.A.-Pipeline by Target, 2016 39

NicOx S.A.-Pipeline by Route of Administration, 2016 40

NicOx S.A.-Pipeline by Molecule Type, 2016 41

NicOx S.A.-Pipeline Products by Mechanism of Action, 2016 43

NicOx S.A.-Recent Pipeline Updates, 2016 44

NicOx S.A.-Dormant Developmental Projects,2016 56

NicOx S.A.-Discontinued Pipeline Products, 2016 57

NicOx S.A., Subsidiaries 59

List of Figures

NicOx S.A.-Pipeline by Top 10 Indication, 2016 8

NicOx S.A.-Pipeline by Stage of Development, 2016 10

NicOx S.A.-Monotherapy Products in Pipeline, 2016 11

NicOx S.A.-Partnered Products in Pipeline, 2016 12

NicOx S.A.-Pipeline by Top 10 Target, 2016 38

NicOx S.A.-Pipeline by Route of Administration, 2016 40

NicOx S.A.-Pipeline by Molecule Type, 2016 41

NicOx S.A.-Pipeline Products by Top 10 Mechanism of Action, 2016 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of NicOx S.A.; NicOx S.A.-Key Therapeutics; NicOx S.A.-Pipeline Overview and Promising Molecules; NicOx S.A.-News; NicOx S.A.-Latest Updates; NicOx S.A.-Pipeline; NicOx S.A.-Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 108825
Site License
USD 3000 INR 217650
Corporate User License
USD 4500 INR 326475



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]